TransFix is a stabilisation reagent that preserves cellular antigens and prevents cellular degradation in a variety of specimen types for flow cytometric analysis.
This study aimed to validate TransFix as a means of stabilising leukocytes in CSF for up to 72 hours following lumbar puncture. Also, to validate antisera panels for TransFix treated CSF samples. Fresh CSF samples were split into two aliquots and analysed fresh or stabilised with TransFix/EDTA.
This study aimed to assess the performance of the TransFix Vacuum Blood Collection Tube (TVT) and BCT
devices across three clinical FC sites for their shared intended purpose of stabilizing lymphocytes for immunophenotyping via flow cytometry for up to 14 days.
Background: The presence of circulating tumor cells (CTCs) has been shown to be of prognostic relevance for patients with early and advanced breast cancer (BC). The usefulness of CTC assessments depends on accurate cell counts and corresponding analysis of molecular targets. The aim of this sub study was to assess the feasibility of a novel, integrated CTC platform for automated cellular protein and nucleic acid analysis in a prospective
multi-center study. The Authors use TransFix to stabilise samples for analysis.
CSF samples were analysed within 2-6 hours of sampling or after 72 hours of storage at +4°C in Transfix.Transfix preserved light scatter and key antigen expression patterns to allow for analysis of diagnostic and follow up CSF specimens for patients with CSN infiltration.